2014's top five US IPO companies still hot this year
This article was originally published in Scrip
Three of the top five drug development firms that completed initial public offerings in the US in 2014 are focused on chimeric antigen receptor T-cell (CAR-T) therapies, but all five of the highest-grossing IPO players last year have one thing in common: later-stage assets for the treatment of high-value indications, like cancer, multiple sclerosis (MS) and anemia.
You may also be interested in...
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.